Evidence map›Paper›PMID 36618080›Full record

ArticleWorld journal of clinical oncology2022

Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?

Andrea Pretta, Eleonora Lai, Clelia Donisi, Dario Spanu, Pina Ziranu, Valeria Pusceddu, Marco Puzzoni, Elena Massa, Mario Scartozzi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Andrea PrettaMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Eleonora LaiMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy. eleonora.lai@unica.it.
Clelia DonisiMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Dario SpanuMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Pina ZiranuMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Valeria PuscedduMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Marco PuzzoniMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Elena MassaMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
Mario ScartozziMedical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy.
University of Cagliari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evaluation of circulating tumor DNA (ctDNA) is increasingly integrated into the management of diagnosis and treatment of gastrointestinal cancer as it represents an innovative and minimally invasive biomarker that could allow us to reach clinical needs not met yet in randomized clinical trials. Recent research provided an interesting overview of the role of circulating tumor DNA in gastric, biliary, liver, pancreatic, and colorectal cancer. Data regarding upper gastrointestinal tumors are currently not practice changing. Tumor detection rates are low in the early stages, while in advanced stages ctDNA is useful for molecular tracking evaluation. Most of the evidence comes from colorectal cancer studies, where ctDNA was evaluated both in the early and advanced stages with the post-surgery minimal residual disease assessment and the response assessment, respectively. ctDNA qualifies as a promising tool in the era of precision medicine, with potential applications in the entire management of gastrointestinal cancer patients. Further evidence is needed to establish which setting may be influenced greatly by liquid biopsy in clinical practice.

Indexed as

Bile duct cancerCirculating tumor DNAColorectal cancerEsophageal cancerGastric cancerGastrointestinal cancerLiquid biopsyLiver cancerPancreatic cancer

Identifiers

PMID36618080
PMCPMC9813836
OpenAlexW4313287943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.